FAP overexpression induce Epithelial-Mesenchymal Transition (EMT) in oral squamous cell carcinoma by down-regulating DPP9 gene.

Qing-qing Wu,^a Meng Zhao,^a Guang-zhao Huang,^a Ze-nan Zheng,^a Wei-sen Zeng,^b
Xiao-zhi Lv^a #

a: Department of Oral & Maxillofacial Surgery, NanFang Hospital, Southern Medical University, Guangzhou, China

b: Wei-sen Zeng: Department of Cell Biology, School of Basic Medical Science, Southern Medical University, Guangzhou, China

Running title: FAP interacts DPP9 in OSCC

Word count of abstract: 150

Word count of methods and materials: 1207

Address correspondence to Xiao-zhi Lv: lxzsurgeon@126.com and Weisen Zeng: zengws@smu.edu.cn

Abstract

FAP acts as a tumor promoter via epithelial-mesenchymal transition (EMT) in human oral squamous cell carcinoma (OSCC). The present study was designed to investigate the interaction proteins with FAP and explore the precise mechanism of FAP promoting EMT in OSCC. IP-MS analysis confirmed that DPP9 was an interacting protein of FAP. DPP9 was down-regulated in OSCC tissue samples compared with MNT using immunohistochemistry and quantitative-PCR detection. Lower DPP9 was correlated with unfavorable overall survival of patients with OSCC. Repressing DPP9 accelerates the proliferation of OSCC cells in vitro and in vivo. Mechanistically, overexpression of FAP downregulate the expression of the DPP9 and the effect of FAP on OSCC proliferation, migration, invasion and EMT could be reversed by up-regulated DPP9. Our study suggests that FAP could induce EMT and promote carcinogenesis in oral squamous cell carcinoma by down-regulating DPP9 gene. That will hint different dimension on therapy for patients with OSCC.

Keyword

OSCC, FAP, DPP9, EMT, Oral cancer

Abbreviations

FAP: fibroblast activation protein

OSCC: Oral squamous cell carcinoma

IP: Immunoprecipitation

MS: Mass spectrometry

qPCR: Quantitative real-time PCR

EMT: Epithelial-mesenchymal transition

Introduction

Cancer of the oral cavity is one of the most common malignancies and an important cause of morbidity and death(1). OSCC accounts for more than 90% of all oral cancers with the main factors of consumption of tobacco and/or alcohol and chewing areca. In spite of major advances in diagnosis and treatment, the prognosis of OSCC is poor due to invasion, metastasis, and recurrence. Although the oral cavity is easily examined, yet up to 60% of OSCC cases are undiagnosed in the clinical stage. At histopathological level, OSCC is characterized squamous differentiation, nuclear pleomorphisms, invasive growth and metastasis(2). The biomarkers(3) for early diagnosis of OSCC is therefore key to improving patient prognosis and survival rates. FAP is a member of the dipeptidyl peptidase (DPP) family with around 50% homology with DPP4(4). FAP is expressed during development, and in the context of cancer, it is highly expressed and can be a marker of cancer-associated fibroblasts(CAFs), and itself has been demonstrated to have pro-tumorigenic activity(5). Structurally, FAP consists of a 6 amino acid cytoplasmic tail, a single 20 amino acid transmembrane domain, and a 734 amino acid extracellular domain(4) and FAP have both post-proline exopeptidase activity and gelatinase activity(6). FAP plays its role in cancer promotion both by enzymatic effects and non-enzymatic effects. Its dual enzymatic

activity gives it a range of putative substrates, and many different types of substrates had been reported(7). Although many studies(7) suggested that FAP can enhance various carcinogenesis process, it is still not clear whether that is based on its enzymatic activity. Emerging(8–10) evidence had suggested FAP's non-enzymatic role in cancer.

Human cancer FAP expression is reported to correlate to higher tumor grade and worse survival across a worldwide range(11),like cancer on the breast, colon, stomach, etc(12–15). Some studies(15, 16) indicated that FAP can induce EMT. Suppressed FAP expression reduced the adhesion, migration, invasion and metastasis of OSCC cells, and EMT plays a key role in previous studies of these phenotypes(17–20). At the same time, EMT-related marker also changed with reduced FAP, such as high expression of E-cadherin, and low expression of N-cadherin. However, the exact mechanism of FAP in EMT and OSCC carcinogenesis is still unknown. Thus, this study was designed to investigate the possible molecular mechanism of FAP in OSCC.

Results

FAP negatively regulate DPP9 in its upstream. The researches currently are limited to its enzymatic activity and its substrates, but the clinical study of the FAP inhibitor Talabostat showed no ideal response. Therefore, it is also important to explore the non-enzymatic activity of FAP. We overexpressed FAP with HIS-tag in SCC9 cell line and conduct IP using anti-HIS antibody to seek the possible interaction proteins with FAP. The lysates from antibody group and IgG group were analyzed by MS, and 14 proteins showed significant difference compared with the IgG group. We focused on DPP9 with 3 filter conditions: subcellular localization, GO function and protein domain⁹ (Fig.1a), and verified it in the antibody group lysate by western blotting (Fig.1b). In SCC9/SCC25 FAP⁺ cell lines, the DPP9 was down-regulated and transiently silencing FAP in SCC15 cell lines, DPP9 expressed lower accordingly. (Fig.1c. $p < 0.05$). In order to explore which site on FAP may relate with DPP9, wild type FAP, intracellular segment deletion type FAP (tFAP) and extracellular segment mutation type FAP (mFAP) in pcDNA3.1+ plasmid were transiently transfected into SCC9 cell lines. Then DPP9 antibody was used to execute IP, and the FAP was detected in four groups of lysates,

observing no FAP in tFAP group. This suggested that intracellular part of FAP may be the cooperating site with DPP9. (Fig.1d) To confirm FAP will not be regulated by DPP9, when transfecting siRNA to silence DPP9, we detected FAP expression in both SCC9 and SCC25 groups and observe FAP no difference (Fig.3a).

Figure 1. Negative correlation between FAP and DPP9.

Coomassie blue staining shows IP lysate with His-antibody. Venn diagram shows the filter condition of 14 peptides from IP-MS. **(b)** Verify DPP9 in IP lysate using DPP9 antibody. **(c)** In FAP-low-expression SCC9 and SCC25, overexpressing FAP and reduced DPP9 can be detected. And in FAP-high-expression SCC15, knockdown FAP shows higher DPP9. All data are represented as mean $\pm$ SD; *p < 0.05. **(d)** Using pcDNA-wFAP/mFAP/tFAP transfecting SCC9 and IP by DPP9 antibody show no blot in tFAP group compared with wFAP/mFAP group.

DPP9 is downregulated in OSCC. Through analysis of DPP9 expression from TCGA head and neck cancer patients in Oncomine, the log² copy number unit of DPP9 was downregulated in head and neck carcinoma samples (290 cases) compared with head and neck part (74 cases) and blood samples (264 cases) (Fig.2a). Three randomized-picked paired OSCC tumor tissues (TUM) and the MNT were analyzed and western blotting revealed that DPP9 protein were markedly low expression in the tumor tissues compared to the MNT. (Fig.2c). DPP9 mRNA expression in Tum was relatively lower in MNT. ($p < 0.0001$, $n=90$, Fig.2d). Also, protein expression levels of DPP9 were measured in samples of 118 pairs archived paraffin-embedded TUM and MNT using IHC ($p < 0.005$, $n=45$) (Fig.2e). Taken together, these results strongly indicate that DPP9 is downregulated in human OSCC.

Fig.2

In Oncomine database (The Cancer Genome Atlas - Head and Neck Squamous Cell Carcinoma DNA Copy Number Data), HNSCC shows lower DPP9 copy number units compared with that in the blood sample and the Head and Neck part. **(b)** Survival

curves (Kaplan–Meier plots) show low-DPP9 is related to a lower survival rate($p=0.02$). **(c)** mRNA level of DPP9 in 90 pairs clinical samples. **(d)** Three random pairs of samples detecting the DPP9 protein expression. **(e)** By IHC and statistical analysis show DPP9 protein level is less in TUM compared with MNT(**** $p<0.0001$). **(f)** mRNA level of DPP9 in 90 pairs clinical samples and egression analysis showed that DPP9 is negatively associated with FAP in OSCC tissues.

Decreased expression of DPP9 is unfavorable for OSCC prognosis. To explore the prognostic value of DPP9 expression for OSCC, the follow-up data of 118 OSCC patients for up to 40months were used to assess the value of DPP9 for predicting patient survival in OSCC patients. These samples were stained using a DPP9 antibody and scored using a standard method (summarized in Table 1). Compared to the adjacent non-tumor OSCC in which DPP9 was strongly detected, DPP9 was undetectable or found to be only expressed at low levels, DPP9 was low expressed in OSCC specimens (Fig.2c). We analyzed the association between DPP9 and the clinicopathological features of OSCC. As showed in Table 1, strong associations were observed between DPP9 expression and clinical stage ($p=0.036$), T classification ($p=0.017$), N classification($p=0.041$). However, the expression of DPP9 was not associated with age, gender and Lymphatic metastasis. Kaplan–Meier survival analysis revealed a correlation between DPP9 expression level and overall survival times ($p=0.02$, Fig.2b). These results indicate a significant correlation of the expression of DPP9 with the prognosis of OSCC.

Table1: Clinicopathological characteristics of patient samples and expression of DPP9 in OSCC

Variables	n	DPP9(%)		P value
		High expression	Low expression	
Age(y)				0.128
≥60	31	13	18	

<60	87	22	65	
Gender				0.115
male	86	29	57	
female	32	6	26	
Clinical stage				0.036
I - II	60	23	37	
III-IV	58	12	46	
T classification				0.017
1	15	8	7	
2	61	19	42	
3	7	2	5	
4	35	6	29	
N classification				0.041
N0-N1	82	29	53	
N2-N3	36	6	30	
Lymphatic invasion				0.358
no	84	27	57	
yes	34	8	26	
Vital states				0.388
alive	33	10	23	
dead	65	16	49	
censored	20	9	11	

DPP9 modulates cell growth of OSCC cells. To evaluate the functional significance of DPP9 on cancer cell proliferation, si-RNA was transfected into SCC9 and SCC25 cell lines to specifically knockdown the expression of DPP9. The effect of siRNA transfection on the expression of DPP9 was confirmed by western blot analysis (Fig.3a, $**p<0.01$). DPP9 knockdown in SCC9 and SCC25 cells promoted cell growth in vitro. Colony formation assay showed that suppressing DPP9 significantly stimulated cell proliferation (Fig.3b). The growth curves determined by CCK-8 assay showed that suppression DPP9 significantly

stimulated cell viability in comparison with si-con cells (Fig.3c). Taken together, these results suggested that DPP9 significantly inhibited cell growth in vitro.

Fig.3

Knockdown of DPP9 causes an anti-tumor effect on OSCC cells. **(a)** Western blot analysis of DPP9 following DPP9 knockdown for 72h. GAPDH was used as an internal control. **(b)** Colony formation assay after knockdown of DPP9 in SCC9 and SCC25 cells for 10 days (*Up*). The mean number of colonies for each well was determined from three independent assays (*Down*). **(c)** Growth rates of SCC9 and SCC25 cells measured by CCK-8 assay after DPP9 knockdown. All data are presented as mean ± SD; *p < 0.05; **p < 0.01; ***p < 0.001 versus control group.

Repression of DPP9 promotes cell migration and invasion in vitro. To investigate the effects of DPP9 on cancer cell metastatic ability, repression of DPP9 in SCC9

and SCC25 cells was conducted to examine the cellular function of invasion and migration. In a wound-healing assay, there was a marked acceleration in the silencing group at the edges of the scratch wound of SCC9 and SCC25 cells (Fig.3c) and Quantitative analysis at 24h confirmed a significant promotion. In addition, Matrigel invasion assays showed SCC9 and SCC25 cells with downregulated DPP9 were much more invasive than controls and the similar tendency in migration assays (Fig.4a, $*p<0.05$, $**p<0.01$, $***p<0.005$).

DPP9 modulates the expression of multiple genes involved in the EMT in OSCC.

Still, use si-DPP9 into SCC9 and SCC25, EMT-associated markers were detected, where the protein level of E-cadherin was decreased while the N-cadherin, Vimentin, SNAIL, was markedly increased in compared with control cells in vitro (Fig.4b). And the phosphorylated ERK1/2 is significantly decreased compared with the control group with similar pan-ERK1/2 expressions. And the proliferation associated protein Cyclin D1, BCL-2 is also detected and shown higher expression.

Fig.4

Depression DPP9 promoted cell migration/invasion and induced EMT in vitro. **(a)** Transwell migration and invasion assay after DPP9 knockdown for 48h. All data are presented as mean $\pm$ SD; * p < 0.05; ** p < 0.01; *** p < 0.001. **(b)** Western blot analysis of p-ERK1/2, ERK, EMT-associated proteins and P53, DPP9, Cyclin D1 following knockdown for 48h. GAPDH was used as an internal control.

DPP9 modulates cell growth of OSCC cells in vivo. To assess the effect of DPP9 of OSCC growth in vivo, DPP9-depleted SCC9 cells, or control cells were injected into nude mice subcutaneously, and then monitored tumor growth. Tumor generation speed of si-DPP9 cells was significantly faster than in control cells, and final volume/weight (20 days) of si-DPP9 group is significantly larger than the SCC9 group(Fig.5a). And the EMT-associated protein in si-DPP9 group change similarly with treated cells in vitro compared with the untreated group by WB

(Fig.5b). All tumors were taken into HE staining and IHC staining using DPP9, CD44, Ki67 (Fig.5c).

Fig.5

DPP9 modulates cell growth of OSCC cells in vivo. **(a)** Tumor formation for 20days after injecting cells to BALBc/nude right armpit. The weight of the tumors and volume change were observed every five days. And the mean weight of tumors for each group was showed in bar graph. **(b)** Western blot analysis of DPP9, FAP, EMT-associated proteins in two tumor tissues each group. **(c)** IHC of CD44, Ki-67 and DPP9 verification and HE staining of each group.

Cell proliferation and migrative/invasive promotion caused by overexpressing

FAP is associated with the DPP9 in OSCC cells. To further delineate the role of DPP9 in the proliferation and migration/invasive regulated by FAP, the expression of DPP9 was restored by pCMV-DPP9 plasmid in FAP-overexpressing SCC9 cells (Fig.6a). As showed in Figure 6, results of the CCK8 assay and colony formation assay demonstrated that the DPP9 plasmid decreased the cell proliferation and tumorigenesis (Fig.6b,6e). Consistently, cells numbers of DPP9 plasmid treated cells of migration and invasion was reduced (Fig.6d). Also, the adhesion test showed further reduction of adhesion ability of the treated cells (Fig.6c). And Western blotting showed reversed expression of, SNAIL1, Vimentin, E-cadherin and N-cadherin, and no significant change of Cyclin D1, β -catenin and BCL-2(Fig.6f). Taken together, these findings suggest that the observed regulation of proliferation, tumorigenesis caused by overexpressing FAP is associated with the DPP9 in OSCC.

Fig 6.

Cell proliferation and migrative/invasive promotion caused by overexpressing FAP is associated with the DPP9 in OSCC cells. **(a)** Verification of DPP9 overexpression in SCC9-FAP⁺ cells by Western Blotting. **(b)** CCK-8 shows decreased growth rate of treated cells. **(c)** Transwell migration and invasion assay after DPP9 overexpressing 48h. **(d)** Up: Colony formation assay after DPP9 plasmid transfecting for 10days. Down: The mean number of colonies for each well was determined from three independent assays. **(e)** Adhesion test showed further reduction of cell adhere ability in the treated group. **(f)** Western blot analysis of N-cadherin, E-cadherin and Vimentin level in SCC9-FAP⁺ cells after treatment with pCMV-DPP9 for 48h. All data are present

ed as mean $\pm$ SD; * p < 0.05; ** p < 0.01; *** p < 0.001 versus control (Blank, Vector)

Discussion

FAP has been considered as a potential immunotherapeutic target(21), and it plays a key role in cancer promotion both by enzymatic effects and non-enzymatic effects. Its enzymatic effects attract more attention so far. Its substrates are partially shared with DPP4(22)-(23). However, Talabostat, the first inhibitor of enzymatic activity of FAP, showed no significant response in clinical trials(24–26). Emerging evidence supports the argument that FAP might affect tumorigenicity independent of its enzymatic activity. Expressing FAP and mutation FAP, both displayed enhanced cancer phenotypes with no significant difference(8). Chung suggested FAP leads to migration and its peptidase activity is not essential for such migration(10). Yang et al.(9) Inhibited FAP with Talabostat does not induce levels of its downstream CCL-2 secretion. Knopf et al.(27) suggested FAP direct bound to erlin-2, stomatin, and caveolin-1. However, it is not clear whether FAP binds to erlin-2, stomatin and caveolin-1 molecules through enzyme activity pattern or non-enzyme activity pattern. FAP may bind to erlin-2 through a non-enzymatic pattern for erlin-2 locating on the endoplasmic reticulum. Therefore, we are committed to exploring the closest downstream effectors on/inside the cell that may mediate the regulation of proliferation and metastasis of FAP, and in 14 proteins analyzed by IP-MS. 2 of 14 proteins are located on the cell membrane and the other 12 are distributed separately on nucleus, cytoplasm, mitochondrion, cytosol, cytoskeleton. We finally focus on DPP9 because of its similar location, likely domain and analogous GO function compared to FAP.

DPP9 belongs to the DPP gene family(28), locates in cell cytosol, expresses ubiquitously in human tissues and mainly enriched in lymphocytes and epithelial cells(29). DPP9 and DPP4 share a high sequence homology, and possess a very similar tertiary structure and functional activity. Not like DPP4, the intracellular functions of DPP9 in human cancer are still unclear. DPP9 has two distinct biological effects on transformed cells in various types of cancer. On the one hand, Lu et al.(30) found DPP9 may act as a survival factor for cells from the Ewing's sarcoma family of tumors cells. Yao(31) reported that DPP9 overexpression can inhibit PI3K/AKT signaling, attenuate cell proliferation and promoting apoptosis in human hepatoma cells(32). On the other hand, DPP9 expression is significantly increased in testicular cancer(29). Thence the

pro- or anti-tumor activity of DPP9 may depend on the cell type and the molecular context within the tumor microenvironment. The functional role of DPP9 in OSCC remains to be elucidated.

In our study, we verified that DPP9 is significantly downregulated in OSCC samples both from TCGA database and in our sample base and the lower DPP9 expression is associated with worse prognosis, including clinical stage, T, N classification and lymph node status. And survival analysis showed that downregulated DPP9 was an independent prognostic factor for poor 3-year overall survival in OSCC patients. Loss-of-function experiments indicated that DPP9 knockdown fostered the colonies forming, cell proliferation speed, migration and invasion of OSCC cells. All these results support an anti-cancer role for DPP9 in OSCC. To the best of our knowledge, this is the first study to explore the clinical prognostic value of DPP9 in OSCC.

EMT has been confirmed to play a significant role in promoting metastasis in epithelium-derived carcinoma. Accumulating evidence has shown that EMT confers adhesion, migration, invasion and metastasis capacity, stemness and multidrug resistance in tumor cells(17–20). When repressing DPP9, the protein level of E-cadherin, which is a hallmark of EMT(19, 33, 34), was decreased while the N-cadherin, SLUG, SNAIL1 was markedly increased in compared with control cells in vitro. And the Vimentin and β -catenin expression cannot be observed changed. We also detect the biomarkers of proliferation and metastasis that may be mediated by DPP9. The expression of MMP2 and Cyclin D1 enhanced while P53 and phosphate-ERK1/2 decreased and GSK-3 β show no difference. Thus, our data and results conclude that the underlying mechanism of DPP9 towards OSCC maybe the EMT properties regulation. Currently, there is not much research on whether DPP9 affects EMT, while Tang.(35) found upregulated DPP9 promotes tumorigenicity and EMT in NSCLC. This difference may be because NSCLC samples in Tang's study included adenocarcinoma and squamous cell carcinoma, which may have a certain impact on the study.

It can be observed the reversed phenotype of tumor growth, migration and invasion when enforcing DPP9 expression in SCC9-FAP⁺ cells. And our conditioned-IP revealed that the intracellular part of FAP might be the possible site interact with DPP9. We reach the conclusion that FAP facilitates cell phenotypes and EMT by down-regulating DPP9. This results innovatively indicate that FAP may induce pro-tumorigenic effects

in a non-enzymatic manner. The extracellular segment containing enzyme active site may not be the only part to promote tumor.

Materials and methods

Cell culture, tissue collection, and Ethics Statement. OSCC cell lines SCC9, SCC25, SCC15 were purchased from ATCC and maintained in DMEM/F12 supplemented with 10% newborn calf serum (NBCS) (Gibco Company, USA). In all, 118 OSCC specimens and matched normal tissues (MNT) were obtained at the time of diagnosis before any therapy from Nanfang Hospital of Southern Medical University, Guangzhou, from 2015 to 2018. In 118 cases, there were 86 males and 32 females. For the use of these clinical materials for research purposes, prior written informed consents from all the patients and approval from the Ethics Committees of Nanfang Hospital of Guangdong Province was obtained (NO: NFEC-2018-027). All specimens had confirmed the pathological diagnosis and were staged according to the 2009 UICC-TNM Classification of Malignant Tumors.

Transient transfection with siRNAs for FAP and DPP9. siRNA for FAP and DPP9 was designed and synthesized by Genepharma (GenePharma Inc., Suzhou, PR China). Twenty-four hours before transfection, SCC9 cells were plated onto a 6-well plate (Jet Bio-Filtration Co., Ltd, Guangzhou, PR China) at a 30–50% confluence. They were then transfected into cells using Lipofectamine3000 Transfection Reagent (Thermos Fishers Co, Ltd., USA) according to the manufacturer's protocol. Cells were collected after 48–72 h for the further experiments. **RNA isolation, reverse transcription, and qRT-PCR.** Total RNA was extracted from the cells using Trizol (Takara, Shiga, Japan). Reverse transcription and qPCR were performed in accordance with the manufacturer's instructions (Vazyme Biotech Co., Ltd, Nanjing). The PCR for each gene was repeated three times. GAPDH was used as an internal control to normalize FAP and DPP9 expression. Differential expression of FAP was calculated using the method.

Plasmid Construction. PFU enzyme (Thermo Fisher, Inc; USA) was used for the PCR program. Using the cDNA from the OSCC samples as template, fragment wild type FAP (wFAP) with HIS-tag was cloned out with primer A and primer B.

Taking wFAP as template, for tFAP (intracellular site deleted), we use primer C and primer B to clone out fragment tFAP. And for mFAP (site 624-704 deleted), we had overlap primer D and primer E. After using primer A and D, primer B and C respectively to clone out fragments F1 and F2, both fragments were added together as templates and cloned out mFAP with primer A and primer E. These three fragments (wFAP, tFAP, mFAP) was cloned into plasmid pcDNA3.1(+) using BamH I and EcoR I . Plasmids was transfected into cells with Lipofectamine3000 Transfection Reagent likely mentioned before. Using the cDNA and primer F/G to clone fragment DPP9 and set it into plasmid pCMV3-Flag with Kpn I and Xba I .

Western blotting. Western blotting was performed using a SDS-PAGE Electrophoresis System according to the previous descriptions with rabbit polyclonal anti-FAP antibody (1: 1000; Santa Cruz Biotechnology Inc., Seattle, USA), mouse monoclonal anti-DPPR2 antibody (1:2000; Santa Cruz Biotechnology Inc., Seattle, USA). Another rabbit polyclonal antibodies contain HIS-tag, GAPDH, E-cadherin, N-cadherin, Vimentin, MMP2, P53, SNAIL, SLUG (1:2000; Proteintech Inc., USA) and pan-ERK1/2 and phosate-ERK1/2(1:2000; CST, USA).

IP assay and MS assay. The total protein was extracted in SCC9-FAP and IP was performed using a Protein A/G Magnetic Beads (Bimake, USA). Briefly, SCC9-FAP⁺ cells were washed with phosphate-buffered saline (PBS), lysed in cold IP lysate buffer, and then centrifuged. Next, the cell lysates were immunoprecipitated with the monoclonal anti-his-tag antibody (Cell Signaling Technology, Inc.; USA) and incubated overnight at 4°C. SDS-PAGE was then conducted to examine the protein levels. The lysate including his-FAP-interacting peptides were collected and submit to a MS facility (Thermo Fisher, Inc.; USA) for analysis. The experiments were repeated three times and the detected peptides were intersected.

Immunohistochemistry (IHC) assay. Examination of DPP9 expression in samples of OSCC and its control tissues by IHC was processed with the DPP9 antibody (1: 50, Abcam Inc., USA). The stained tissue sections were reviewed and scored independently by two pathologists blinded to the clinical parameters. The

staining score standard has also been described. For statistical analysis of DPP9 expression in noncancerous tissues against OSCC tissues, staining scores of 0–5 and 6–10 were respectively considered to be a low and high expression.

CCK-8 assay. Cell Counting Kit-8 assay was used to evaluate the rate of in vitro cell proliferation. For siDPP9 cells, they were seeded in 96-well plates at a density of 1000 cells/well and respectively incubated for 12, 24, 48, 70 hours. 10μl of CCK-8 (DOJINDO LABORATORIES Ltd., China) was added to each well and incubated for 4 h. The absorbance value (OD) of each well was measured at 450nm. Experiments were carried out three times.

Colony formation assay. Placing 1,0000 treated cells per well in 6-well plates and after their attachment, there is no contact between cells. Incubate the cells in a CO₂ incubator at 37°C for 10-15days until cells have formed colonies with substantial good size (50 cells per colony). Remove medium and rinse cells with PBS 2 times, and add 1ml methanol per well at room temperature (RT) for 5 min. Remove methanol and add 0.5% crystal violet carefully and incubate at RT for 2h. Remove crystal violet and immerse the plates in tap water to rinse off crystal violet. Air-dry the plates at RT for a day. Scan the plates into image and count number of colonies, then calculate plating efficiency(PE) by the quotation $PE = \frac{\text{no. of colonies formed}}{\text{no. of cells seeded}} \times 100\%$.

Invasion and migration assays. For the invasion assay, cells were seeded in 100 ml DMEM/F12 media on the top of polyethylene terephthalate (PET) membranes coated with Matrigel TM (1.5 mg/ml, BD Biosciences Inc.) within transwell cell culture inserts (24-well inserts, 8 mm pore size; Corning Life Sciences, Corning, NY, USA). The bottom chamber was filled with 600 ml of DMEM/F12 media containing 20% FBS. The cells were incubated for 12 h at 37°C with 5% CO₂. Subsequently, the cells were fixed in 2.5% (v/v) glutaraldehyde and stained with 0.1% crystal violet. For the migration assay, the same of the invasion assay without Matrigel TM. Both cells on the membranes bottom were visualized under a microscope (Zeiss Ltd., China) and quantified by counting the number of cells in three randomly chosen fields at 200-fold magnification.

In vivo tumor growth assay. BALB/c-nude mice (4 weeks old, 18-20g) were

purchased from The Laboratory Animal Centre, Southern Medical University. The Institutional Animal Care and Use Committee of Southern Medical University approved all experimental procedures. Cells were harvested by trypsinization, washed twice with cold serum-free medium, and resuspended with serum-free medium. To evaluate cancer growth in vivo, 2×10^6 treated cells were independently injected subcutaneously into the left axilla in 5 nude mice each group. Every five days, the length (L) and width (W) of tumors were measured using calipers, and their volumes were calculated using the equation $(L \times W^2)/2$. On day 20th, the animals were euthanized, and the tumors were excised, weighed, serial sliced and stained with hematoxylin and eosin (HE).

Statistical analysis. SPSS 24.0 software (SPSS Inc., Chicago, IL, USA) and GraphPad software (GraphPad Software, Inc., La Jolla, CA, USA) was used to analyze all data for statistical significance. Two-tailed Student's t-test was used for comparisons of two independent groups. One-way ANOVA was used to determine differences between groups for all in vitro analyses. A $p < 0.05$ was considered statistically significant.

Conclusion

Overall, our study suggests that FAP induces EMT by down-regulating DPP9 gene in OSCC. DPP9 may play a potential tumor depression role in OSCC. DPP9 overexpression was able to reverse tumorigenesis and metastasis caused by FAP in OSCC cells. These could be a vigorous therapeutic strategy for future OSCC treatment, but the specific mechanism and functional sites still need to be further explored.

Acknowledgments

QQW carried out her thesis research under the auspices of the NanFang Hospital, Southern Medical University and Department of Cell Biology, School of Basic Medical Science, Southern Medical University, Guangzhou, China.

Ethics approval and consent to participate

The study protocol was approved by the Ethics Committees of Nanfang Hospital of Guangdong Province (NO: NFEC-2018-027).

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Funding

This study was supported by National Natural Science Foundation of China (General Program: 81472536), Science and Technology Planning Project of Guangdong Province of China(No:2017A020215181), the Southern Medical University Scientific Research Fund (CX2018N016), Project of Educational Commission of Guangdong Province of China (2018KTSCX026), and the Presidential Foundation of the Nanfang Hospital (2014027).

Reference

1. Siegel RL, Miller KD, Jemal A. 2019. Cancer statistics, 2019. CA Cancer J Clin 69:7–34.
2. Nosratzahi T. 2017. Salivary Chemical Factors in Relation with Oral Cancer in Smokers and Non-Smokers: a Literature Review. J Dent (Shiraz) 18:237–243.
3. Shao T, Huang J, Zheng Z, Wu Q, Liu T, Lv X. 2018. SCCA, TSGF, and the Long Non-Coding RNA AC007271.3 are Effective Biomarkers for Diagnosing Oral Squamous Cell Carcinoma. Cell Physiol Biochem 47:26–38.

- 456 4. Scanlan MJ, Raj BK, Calvo B, Garin-Chesa P, Sanz-Moncasi MP, Healey JH,
457 Old LJ, Rettig WJ. 1994. Molecular cloning of fibroblast activation protein
458 alpha, a member of the serine protease family selectively expressed in
459 stromal fibroblasts of epithelial cancers. *Proc Natl Acad Sci USA* 91:5657–
460 5661.
- 461 5. Hamson EJ, Keane FM, Tholen S, Schilling O, Gorrell MD. 2014.
462 Understanding fibroblast activation protein (FAP): substrates, activities,
463 expression and targeting for cancer therapy. *Proteomics Clin Appl* 8:454–463.
- 464 6. Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ, Rettig WJ. 1999.
465 Fibroblast activation protein, a dual specificity serine protease expressed in
466 reactive human tumor stromal fibroblasts. *J Biol Chem* 274:36505–36512.
- 467 7. Puré E, Blomberg R. 2018. Pro-tumorigenic roles of fibroblast activation
468 protein in cancer: back to the basics. *Oncogene* 37:4343–4357.
- 469 8. Lv B, Xie F, Zhao P, Ma X, Jiang WG, Yu J, Zhang X, Jia J. 2016. Promotion of
470 Cellular Growth and Motility Is Independent of Enzymatic Activity of
471 Fibroblast Activation Protein- α . *Cancer Genomics Proteomics* 13:201–208.
- 472 9. Yang X, Lin Y, Shi Y, Li B, Liu W, Yin W, Dang Y, Chu Y, Fan J, He R. 2016. FAP
473 Promotes Immunosuppression by Cancer-Associated Fibroblasts in the
474 Tumor Microenvironment via STAT3-CCL2 Signaling. *Cancer Res* 76:4124–
475 4135.

- 476 10. Chung K-M, Hsu S-C, Chu Y-R, Lin M-Y, Jiaang W-T, Chen R-H, Chen X.
477 2014. Fibroblast activation protein (FAP) is essential for the migration of bone
478 marrow mesenchymal stem cells through RhoA activation. PLoS ONE
479 9:e88772.
- 480 11. Liu F, Qi L, Liu B, Liu J, Zhang H, Che D, Cao J, Shen J, Geng J, Bi Y, Ye L, Pan
481 B, Yu Y. 2015. Fibroblast activation protein overexpression and clinical
482 implications in solid tumors: a meta-analysis. PLoS ONE 10:e0116683.
- 483 12. Busek P, Balaziová E, Matrasová I, Hilser M, Tomas R, Syruček M, Zemanová
484 Z, Krepela E, Belacek J, Sedo A. 2016. Fibroblast activation protein alpha is
485 expressed by transformed and stromal cells and is associated with
486 mesenchymal features in glioblastoma. Tumour Biol 37:13961–13971.
- 487 13. Park CK, Jung WH, Koo JS. 2016. Expression of cancer-associated fibroblast-
488 related proteins differs between invasive lobular carcinoma and invasive
489 ductal carcinoma. Breast Cancer Res Treat 159:55–69.
- 490 14. Jung YY, Lee YK, Koo JS. 2015. Expression of cancer-associated fibroblast-
491 related proteins in adipose stroma of breast cancer. Tumour Biol 36:8685–
492 8695.
- 493 15. Errarte P, Guarch R, Pulido R, Blanco L, Nunes-Xavier CE, Beitia M, Gil J,
494 Angulo JC, López JI, Larrinaga G. 2016. The Expression of Fibroblast
495 Activation Protein in Clear Cell Renal Cell Carcinomas Is Associated with

496 Synchronous Lymph Node Metastases. PLoS ONE 11:e0169105.

497 16. Wang H, Wu Q, Liu Z, Luo X, Fan Y, Liu Y, Zhang Y, Hua S, Fu Q, Zhao M,
498 Chen Y, Fang W, Lv X. 2014. Downregulation of FAP suppresses cell
499 proliferation and metastasis through PTEN/PI3K/AKT and Ras-ERK signaling
500 in oral squamous cell carcinoma. Cell Death Dis 5:e1155.

501 17. Lu W, Kang Y. 2019. Epithelial-Mesenchymal Plasticity in Cancer Progression
502 and Metastasis. Dev Cell 49:361–374.

503 18. Kalluri R, Weinberg RA. 2009. The basics of epithelial-mesenchymal transition.
504 J Clin Invest 119:1420–1428.

505 19. Acloque H, Adams MS, Fishwick K, Bronner-Fraser M, Nieto MA. 2009.
506 Epithelial-mesenchymal transitions: the importance of changing cell state in
507 development and disease. J Clin Invest 119:1438–1449.

508 20. van Zijl F, Mall S, Machat G, Pirker C, Zeillinger R, Weinhaeusel A, Bilban M,
509 Berger W, Mikulits W. 2011. A human model of epithelial to mesenchymal
510 transition to monitor drug efficacy in hepatocellular carcinoma progression.
511 Mol Cancer Ther 10:850–860.

512 21. Jiang G-M, Xu W, Du J, Zhang K-S, Zhang Q-G, Wang X-W, Liu Z-G, Liu S-
513 Q, Xie W-Y, Liu H-F, Liu J-S, Wu B-P. 2016. The application of the fibroblast
514 activation protein α -targeted immunotherapy strategy. Oncotarget 7:33472–
515 33482.

- 516 22. Keane FM, Nadvi NA, Yao T-W, Gorrell MD. 2011. Neuropeptide Y, B-type
517 natriuretic peptide, substance P and peptide YY are novel substrates of
518 fibroblast activation protein- α . FEBS J 278:1316–1332.
- 519 23. Koczorowska MM, Tholen S, Bucher F, Lutz L, Kizhakkedathu JN, De Wever
520 O, Wellner UF, Biniossek ML, Stahl A, Lassmann S, Schilling O. 2016.
521 Fibroblast activation protein- α , a stromal cell surface protease, shapes key
522 features of cancer associated fibroblasts through proteome and degradome
523 alterations. Mol Oncol 10:40–58.
- 524 24. Narra K, Mullins SR, Lee H-O, Strzemkowski-Brun B, Magalong K,
525 Christiansen VJ, McKee PA, Egleston B, Cohen SJ, Weiner LM, Meropol NJ,
526 Cheng JD. 2007. Phase II trial of single agent Val-boroPro (Talabostat)
527 inhibiting Fibroblast Activation Protein in patients with metastatic colorectal
528 cancer. Cancer Biol Ther 6:1691–1699.
- 529 25. Eager RM, Cunningham CC, Senzer N, Richards DA, Raju RN, Jones B,
530 Uprichard M, Nemunaitis J. 2009. Phase II trial of talabostat and docetaxel in
531 advanced non-small cell lung cancer. Clin Oncol (R Coll Radiol) 21:464–472.
- 532 26. Eager RM, Cunningham CC, Senzer NN, Stephenson J, Anthony SP, O'Day SJ,
533 Frenette G, Pavlick AC, Jones B, Uprichard M, Nemunaitis J. 2009. Phase II
534 assessment of talabostat and cisplatin in second-line stage IV melanoma.
535 BMC Cancer 9:263.

- 536 27. Knopf JD, Tholen S, Koczorowska MM, De Wever O, Biniossek ML, Schilling
537 O. 2015. The stromal cell-surface protease fibroblast activation protein- α
538 localizes to lipid rafts and is recruited to invadopodia. *Biochim Biophys Acta*
539 1853:2515–2525.
- 540 28. Liu J, Huan Y, Li C, Liu M, Shen Z. 2014. Establishment of a selective evaluation
541 method for DPP4 inhibitors based on recombinant human DPP8 and DPP9
542 proteins. *Acta Pharm Sin B* 4:135–140.
- 543 29. Yu DMT, Ajami K, Gall MG, Park J, Lee CS, Evans KA, McLaughlin EA, Pitman
544 MR, Abbott CA, McCaughan GW, Gorrell MD. 2009. The in vivo expression of
545 dipeptidyl peptidases 8 and 9. *J Histochem Cytochem* 57:1025–1040.
- 546 30. Lu C, Tilan JU, Everhart L, Czarnecka M, Soldin SJ, Mendu DR, Jeha D, Hanafy
547 J, Lee CK, Sun J, Izycka-Swieszewska E, Toretsky JA, Kitlinska J. 2011.
548 Dipeptidyl peptidases as survival factors in Ewing sarcoma family of tumors:
549 implications for tumor biology and therapy. *J Biol Chem* 286:27494–27505.
- 550 31. Yao T-W, Kim W-S, Yu DMT, Sharbeen G, McCaughan GW, Choi K-Y, Xia P,
551 Gorrell MD. 2011. A novel role of dipeptidyl peptidase 9 in epidermal growth
552 factor signaling. *Mol Cancer Res* 9:948–959.
- 553 32. Spagnuolo PA, Hurren R, Gronda M, MacLean N, Datti A, Basheer A, Lin F-H,
554 Wang X, Wrana J, Schimmer AD. 2013. Inhibition of intracellular dipeptidyl
555 peptidases 8 and 9 enhances parthenolide's anti-leukemic activity. *Leukemia*

556 27:1236–1244.

557 33. van Roy F, Berx G. 2008. The cell-cell adhesion molecule E-cadherin. *Cell Mol*

558 *Life Sci* 65:3756–3788.

559 34. Peinado H, Olmeda D, Cano A. 2007. Snail, Zeb and bHLH factors in tumour

560 progression: an alliance against the epithelial phenotype? *Nat Rev Cancer*

561 7:415–428.

562 35. Tang Z, Li J, Shen Q, Feng J, Liu H, Wang W, Xu L, Shi G, Ye X, Ge M, Zhou X,

563 Ni S. 2017. Contribution of upregulated dipeptidyl peptidase 9 (DPP9) in

564 promoting tumoregenicity, metastasis and the prediction of poor prognosis

565 in non-small cell lung cancer (NSCLC). *Int J Cancer* 140:1620–1632.

566

567

A.

B.